Background Treatment of aggressive pituitary adenomas typically involves a multimodality
approach based on histopathological features and may include pharmacotherapy, surgery …

Temozolomide is effective in some patients with progressive pituitary adenoma or
carcinoma. We report a survey study of Italian patients treated with Temozolomide because …

Pituitary adenomas are benign intracranial neoplasms that are frequently well-controlled
with standard treatments that include surgical resection, radiotherapy, and agents that …

Objectives Only few retrospective studies have reported an efficacy rate of temozolomide
(TMZ) in pituitary tumors (PT), all around 50%. However, the long-term survival of treated …

OBJECTIVE: The management of aggressive pituitary macroadenomas represents a
challenge to neurosurgeons. These tumors are very difficult to treat, owing mainly to their …

Background Pituitary carcinomas (PC) and atypical pituitary adenomas (APA) are rare
variants of pituitary tumors for which no evidence-based treatment currently exists. We …

Abstract Purpose Aggressive pituitary adenomas (APAs) and pituitary carcinomas (PCs) are
challenging for their invasive nature, resistance to treatment and recurrences …

Objective The prognosis of either pituitary carcinoma or aggressive pituitary adenoma
resistant to standard therapies is poor. We assessed the efficacy of treatment with …

The rare aggressive pituitary adenoma presents a special challenge, due to the
heterogenous presentation of the disease. The prognosis of aggressive pituitary adenomas …

We evaluated results of temozolomide (TMZ) therapy in six patients, aged 34–78 years,
presenting aggressive pituitary tumors. In all the patients tested O6‐methylguanine‐DNA …